HC Wainwright Forecasts Clene’s Q1 Earnings (NASDAQ:CLNN)

Clene Inc. (NASDAQ:CLNN) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Clene in a research report issued to clients and investors on Monday, March 24th. HC Wainwright analyst J. Pantginis expects that the company will earn ($1.11) per share for the quarter. HC Wainwright has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. HC Wainwright also issued estimates for Clene’s Q2 2025 earnings at ($1.15) EPS, Q3 2025 earnings at ($1.28) EPS, Q4 2025 earnings at ($1.35) EPS, FY2025 earnings at ($4.92) EPS, FY2026 earnings at ($3.02) EPS and FY2027 earnings at $0.52 EPS.

Separately, D. Boral Capital restated a “buy” rating and set a $23.00 price objective on shares of Clene in a research note on Monday. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $55.25.

Clene Stock Performance

Shares of CLNN opened at $3.46 on Wednesday. The company has a 50 day moving average price of $4.52 and a 200-day moving average price of $4.89. Clene has a fifty-two week low of $3.37 and a fifty-two week high of $9.20. The stock has a market capitalization of $28.81 million, a PE ratio of -0.66 and a beta of 0.27.

Clene (NASDAQ:CLNN) last announced its quarterly earnings data on Monday, March 24th. The company reported ($1.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.46). The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.13 million. Clene had a negative net margin of 8,556.77% and a negative return on equity of 1,106.30%.

Hedge Funds Weigh In On Clene

Several large investors have recently made changes to their positions in the company. Fullcircle Wealth LLC purchased a new position in Clene in the fourth quarter valued at $69,000. SBI Securities Co. Ltd. acquired a new stake in shares of Clene during the 4th quarter valued at about $69,000. Renaissance Technologies LLC purchased a new position in shares of Clene in the 4th quarter valued at about $96,000. Parsons Capital Management Inc. RI acquired a new position in Clene in the 4th quarter worth about $194,000. Finally, Geode Capital Management LLC boosted its position in Clene by 52.9% during the fourth quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock worth $346,000 after purchasing an additional 22,539 shares in the last quarter. 23.28% of the stock is currently owned by institutional investors and hedge funds.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.